Betapace AF Education Will Emphasize Use Only For Severe Symptoms
Executive Summary
Berlex' Betapace AF educational program should emphasize use only in highly symptomatic patients, FDA said in its Feb. 22 approval letter for sotalol for atrial fibrillation and atrial flutter.
You may also be interested in...
Berlex Betapace Indication Should Specify Normal Sinus Rhythm - Cmte.
Berlex' Betapace indication for atrial fibrillation patients should include language emphasizing the anti-arrhythmic's intended use in patients in normal sinus rhythm rather than for conversion from atrial fibrillation or flutter, FDA's Cardio-Renal Drugs Advisory Committee members told the agency April 29.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials